ArticleHaematologica2019

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

José A García-Marco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.